Machine signal
Active cluster sell — 4 distinct insiders, $2.1M, window ends Aug 19, 2026.
Figures computed from official regulatory filings — .
Analysttarget 13 USD (+173%) · consensus 4.62/5 · 12 buy · 1 hold · 0 sell
Ownershipinsiders 17.19% · institutions 67.64% · short 27.6% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Nuvation Bio Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
41 buys29 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Hattersley Gary | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Hattersley Gary | Sell | $709.2K | SEC |
| Hattersley Gary | Exercise | $187K | SEC |
| Sauvage Philippe | Exercise | $86.8K | SEC |
| Sauvage Philippe | Exercise | $2 | SEC |
| Sauvage Philippe | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sauvage Philippe | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Markel Stacy | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Markel Stacy | Exercise | $60.2K | SEC |
| Sauvage Philippe | Sell | $286.4K | SEC |
| Sauvage Philippe | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Wentworth Kerry | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Markel Stacy | Sell | $753.2K | SEC |
| Wentworth Kerry | Exercise | $184.6K | SEC |
| Markel Stacy | Exercise | $169K | SEC |
| Wentworth Kerry | Sell | $379.2K | SEC |
| Markel Stacy | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sauvage Philippe | Exercise | $103.4K | SEC |
| Mashal Roberttrack record | Buy | $118.3K | conv 33First in 12mo | SEC |
| Cui Xiangmintrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FALBERG KATHRYN Etrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| VERNON W ANTHONY | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Bazemore Robert Btrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cui Xiangmintrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mashal Roberttrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |